AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31392363
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estrogen treatment
Trial: 31392363
Drug: Local estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local estrogen treatment (LET)
Trial: 10902991
Drug: Energy supplement
RxNorm normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy supplement (E) = 1171 kJ + 12 mg iron
Trial: 10902990
Drug: Micronutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplement (M) = 12 mg iron + 209 kJ
Trial: 26933849
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles
Trial: 26933849
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles
Trial: 26933849
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients not receiving bevacizumab
Trial: 26933849
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients not receiving bevacizumab
Trial: 26933849
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m²) plus carboplatin (AUC 6) for six cycles among patients receiving bevacizumab
Trial: 26933849
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC 6) every 3 weeks for six cycles among patients receiving bevacizumab
Trial: 25637379
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel
Trial: 18405787
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg/d, n=131)
Trial: 18405787
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus diuretics
Trial: 15660392
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a (180 microg once weekly for 48 weeks)
Trial: 7017171
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cinoxacin
Trial: 7017171
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g nalidixic acid 4 times daily
Trial: 31104069
Drug: Thrombomodulin (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombomodulin (0.06 mg/kg/d, maximum 6 mg/d) administered as an intravenous bolus or a 15-minute infusion once daily for 6 days (n = 395)
Trial: 19439041
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue factor pathway inhibitor (rTFPI)
Trial: 17319797
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg etomoxir
Trial: 17319797
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg etomoxir
Trial: 6712870
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg daily)
Trial: 2577460
Drug: Slow-release oxprenolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oxprenolol (160 mg)
Trial: 769697
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% solution or cream formulation
Trial: 30795492
Drug: Risperidone adjunct
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone adjunct therapy for 0 weeks
Trial: 20091317
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Trial: 20091317
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Trial: 2653395
Drug: Dextropropoxyphene 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene 180 mg and Paracetamol 1.95 g daily (D&P)
Trial: 9040545
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (60 mg)
Trial: 8424280
Drug: Propofol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2 mg.kg‐1 i.v.)
Trial: 8424280
Drug: Flunitrazepam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.03 mg.kg‐1 i.v.)
Trial: 26826533
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment for 6 weeks
Trial: 11999466
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg once daily (o.d.)
Trial: 10411249
Drug: Oxygenator coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygenator coated with albumin in the priming solution
Trial: 7547213
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg i.v. 30 min after cisplatin or 16 mg orally at the end of cisplatin infusion)
Trial: 7547213
Drug: Buspirone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later)
Trial: 1372924
Drug: Large volume
RxNorm normalized name: NEBULIZER,LARGE VOLUME #1770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large volume paracentesis (LVP) and infusion of low molecular weight dextran (n = 20)
Trial: 1372924
Drug: Aldactone 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldactone 400 mg/day and furosemide 80 mg/day (n = 20)
Trial: 9051202
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (300 mg)
Trial: 11427639
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (250 mg)
Trial: 9051202
Drug: Beta-carotene (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (15 mg)
Trial: 7581831
Drug: Combined supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplement (vitamin E, vitamin C, beta-carotene)
Trial: 12894131
Drug: Alefacept (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept (12 weekly intramuscular or intravenous injections)
Trial: 26826274
Drug: Sequential media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential media (Quinn's Advantage Cleavage Medium followed by Blast Assist)
Trial: 19523617
Drug: Sequential media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential media
Trial: 25532586
Drug: Low-dose Saccharum
RxNorm normalized name: Acer saccharum pollen
DrugBank: Acer saccharum pollen (DB10369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose Saccharum iron (200 mg/dose, once a week for 5 weeks, total 1000 mg)
Trial: 16650135
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 300 mg daily
Trial: 6322906
Drug: More than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than 20 days treatment with sodium stibogluconate if necessary
Trial: 6322906
Drug: More than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than 20 days treatment with sodium stibogluconate
Trial: 17890954
Drug: Ultrahigh-dose streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrahigh-dose streptokinase (UH-SK n = 8)
Trial: 14981602
Drug: Continuous venovenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous venovenous hemofiltration (CVVH) with an ultrafiltration rate of 1 L/h
Trial: 14981602
Drug: Continuous venovenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous venovenous hemofiltration (CVVH) with an ultrafiltration rate of 2.5 L/h
Trial: 14981602
Drug: Continuous venovenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous venovenous hemodialysis (CVVHD) with a dialysate flow rate of 1 L/h
Trial: 11782981
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with tissue plasminogen activator
Trial: 27920119
Drug: Telephone coaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone coaching by a family physician (twice a month)
Trial: 25216712
Drug: Linseed oil
RxNorm normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linseed oil (α-linolenic acid; 7 g ALA/day)
Trial: 25216712
Drug: Echium oil
RxNorm normalized name: Echium plantagineum seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echium oil (stearidonic acid; 2 g SDA/day)
Trial: 23431993
Drug: 25‐mg meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐mg meperidine
Trial: 22080314
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 × 5 g Cr monohydrate per day)
Trial: 22080314
Drug: Placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplementation (4 × 5 g maltodextrin per day)
Trial: 9402175
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of chemotherapy cycles > 6
Trial: 30541474
Drug: Yoga (60-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga (60-min sessions, 2x weekly for 10 weeks)
Trial: 30541474
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education (90-min sessions, weekly for 10 weeks)
Trial: 27383312
Drug: Organic melon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic melon (250 g per day for 15 days)
Trial: 27383312
Drug: Market melon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Market melon (250 g per day for 15 days)
Trial: 20051299
Drug: Sitagliptin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin plus G-CSF
Trial: 16230562
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid (5-ALA) pretreatment followed by intense pulsed light (IPL) treatment
Trial: 16230562
Drug: IPL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL treatment alone
Trial: 11851783
Drug: Nurse-administered 'side-effect'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered 'side-effect' checklists
Trial: 2253903
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml radiolabelled beef consommé with 60 g margarine
Trial: 2253903
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml radiolabelled beef consommé without margarine
Trial: 21828142
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg daily
Trial: 12783373
Drug: IFN up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN up to 5 MU/m(2)/d with cytarabine (Ara‐C) 20 mg/m(2)/d for 10 days every month
Trial: 28829155
Drug: Ashwagandha root
RxNorm normalized name: ashwagandha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha root extract (600 mg daily)
Trial: 27348483
Drug: Ledipasvir/sofosbuvir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/sofosbuvir plus GS-9669 500 mg for 8 weeks
Trial: 25102686
Drug: Zaizaoshengxue tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaizaoshengxue tablets
Trial: 15786529
Drug: Sucralfate 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1,000 mg thrice daily
Trial: 15786529
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 10 mg thrice daily
Trial: 12088306
Drug: Methylphenidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.3 mg/kg, twice daily
Trial: 12088306
Drug: Methylphenidate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.5 mg/kg, twice daily
Trial: 9682182
Drug: Modafinil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (300 mg x 2) during sleep deprivation (N1)
Trial: 9682182
Drug: Modafinil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (300 mg x 2) and Placebo during recovery and control nights (N2)
Trial: 7878164
Drug: Caffeine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.5 mg/kg bodyweight)
Trial: 7878164
Drug: Smoking (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking (1.2 mg nicotine yield from cigarette with 8 cued puffs)
Trial: 41543
Drug: Temazepam 15
RxNorm normalized name: temazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 15 mg (short-term study)
Trial: 22882353
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol (300,000 IU in six divided doses over 3 months)
Trial: 22882353
Drug: Intramuscular cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular cholecalciferol (300,000 IU as a single injection)
Trial: 17352284
Drug: Antiresorptive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive agents (bisphosphonates)
Trial: 31855009
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy for Depression plus Brief Motivational Interviewing (CBT-D + BMI)
Trial: 31855009
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy for Depression (CBT-D)
Trial: 29794306
Drug: JNJ‐39439335 (2-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐39439335 (2-50 mg)
Trial: 26651333
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (100 μg or 200 μg)/vilanterol 25 μg
Trial: 26651333
Drug: Existing asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Existing asthma maintenance therapy
Trial: 23725677
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g)
Trial: 20948459
Drug: anterior injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anterior injection followed by laser
Trial: 20948459
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg triamcinolone acetonide anterior injection
Trial: 20948459
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone acetonide posterior injection
Trial: 20948459
Drug: posterior injection
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: posterior injection followed by laser
Trial: 14983953
Drug: Threshold tPSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold tPSA of >= 4.0 ng/mL
Trial: 14983953
Drug: Threshold tPSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold tPSA of >= 3.0 ng/mL combined with f/tPSA threshold of <= 18%
Trial: 31701163
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo
Trial: 2022158
Drug: Omeprazole, 10
RxNorm normalized name: Omeprazole, 10 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 10 mg every morning
Trial: 8003642
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg every morning
Trial: 1095098
Drug: 400 rads
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 rads twice weekly for four weeks
Trial: 24089693
Drug: 1-week free
RxNorm normalized name: Free Cysteine
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-week free nicotine replacement therapy (NRT) with behavioural counselling
Trial: 24089693
Drug: 2-week free
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week free nicotine replacement therapy (NRT) with behavioural counselling
Trial: 19289640
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR of 2.5 to 3.0)
Trial: 19289640
Drug: Aspirin (162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (162 mg once daily)
Trial: 12171689
Drug: Oral supplement
RxNorm normalized name: Healios Oral Supplement Unflavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplement containing glucosamine, amino acids, minerals, and antioxidants
Trial: 12171689
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (12 individuals who did not take the supplement)
Trial: 7919326
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose (500 mL of plasma)
Trial: 7919326
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mL of 5% human serum albumin)
Trial: 3277494
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists in combination with diuretics
Trial: 3277494
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose diuretic and calcium blocker
Trial: 31914324
Drug: Doxazosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (8 mg/day)
Trial: 7955823
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of lomefloxacin
Trial: 7955823
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of lomefloxacin
Trial: 30696483
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ixekizumab every 2 weeks (IXEQ2W)
Trial: 28294430
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg etanercept (ETN) twice weekly
Trial: 22779217
Drug: SRP combined
RxNorm normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP combined with 1.7% hydrogen peroxide gel (Perio Gel) using custom trays
Trial: 21980827
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg/day)
Trial: 17555327
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g of DNJ-enriched powder (12 mg of DNJ)
Trial: 8209276
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by radiotherapy (arm B)
Trial: 2563311
Drug: Prazosin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (mean dose, 5 mg per day)
Trial: 2563311
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean dose, 133 mg per day)
Trial: 19967563
Drug: Placebo (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (900 mg per day for 6 months)
Trial: 8875514
Drug: Glutamine-supplemented total
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-supplemented total parenteral nutrition (GTPN) with 25 g crystalline L-glutamine per 24 h
Trial: 8875514
Drug: Conventional total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional total parenteral nutrition (CTPN)
Trial: 1411294
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g four times daily)
Trial: 9887898
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicines (CHMs)
Trial: 18419878
Drug: budesonide DPI-B
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide DPI-B 360 microg twice-daily (total daily dose 720 microg)
Trial: 18419878
Drug: budesonide DPI-A
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide DPI-A 400 microg twice-daily (total daily dose 800 microg)